Although the NF-κB pathway serves as a key factor in EBV latent infection and oncogenesis, the intricate and intertwined regulatory network of EBV antigens and NF-κB factors presents a significant challenge for the development of anti-EBV therapeutic strategies in EBV-related diseases. Here, NFKB1 is linked to disease arising from reactivation of latent virus.